Clinical Trials on Plasma Concentration of Mirabegron in United States

Total 214 results

University of Virginia
The University of Queensland

Completed

Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery

Plasma Concentration of Antibiotics

United States
PepsiCo Global R&D

Completed

Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy Volunteers

Plasma Caffeine Concentration

United States
AcelRx Pharmaceuticals, Inc.

Completed

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Plasma Concentrations

United States
AstraZeneca

Completed

Explore the Performance of IntelliCap.

Pharmacokinetic Profile | Plasma Concentration

United Kingdom
Newcastle University

Unknown

Effects of Quinoa Consumption on Markers of Cardiovascular Risk and Gastrointestinal Health

Change in Fasting Plasma LDL-cholesterol Concentration After the Consumption of Quinoa

United Kingdom
Astellas Pharma Inc

Completed

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Astellas Pharma Inc

Completed

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
PepsiCo Global R&D

Completed

Processed Orange and the Glycemic Response (POGR)

Maximum Observed Plasma Glucose Concentration (Cmax)

United States
King's College London

Completed

Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia

Healthy Men | Raised Fasting Plasma Triacylglycerol Concentrations

United Kingdom
Midwest Vein Center

Unknown

Efficacy of Variable Lidocaine Concentrations in Tumescent Anesthesia for Pain Control During and After Endovenous Laser Procedure; Non-inferiority Trial

Pain During and After Endovenous Laser Obliteration of Large Saphenous Vein Based on Lidocaine Tumescent Concentration

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects

Healthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Plasma Mycophenolic Acid (MPA) | Pharmacokinetics of Plasma Phenolic Glucuronide of MPA (MPAG)

United States
Research & Diagnostic Antibodies
National Institute of General Medical Sciences (NIGMS)

Completed

Normal Human Plasma Level of iNOS Study

Normal Human Plasma Level of iNOS

United States
Centagen, Inc.

Completed

Effects of a 10 Component Dietary Supplement on Health and the Quality of Life

Quality of Life | Stress | Blood Pressure | Joint Instability | Immune Deficiency | Lung Function Decreased | HDL Low | Energy Supply; Deficiency | Concentration Ability Impaired

United States
Octapharma

Completed

Octaplas Pediatric Plasma Exchange Trial (Octaplas)

Adverse Effects in the Therapeutic Use of Plasma Substitutes

United States
Metabolic Technologies Inc.

Completed

Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses

Focus of the Study is to Examine Plasma HMB Levels After Oral HMB Supplementation

United States
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Evaluation of Lipoproteins

Evaluation of Plasma Lipoproteins

United States
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
Maco Productions S.A.S.
SynteractHCR

Completed

A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma

Adverse Effects in the Therapeutic Use of Plasma Substitutes

United Kingdom, Belgium, Greece, Spain
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (B-SCR-MM)

Multiple Myeloma | AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Dyscrasias

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
Roswell Park Cancer Institute

Completed

Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Myeloma

United States
University of Pennsylvania

Completed

The Effect of a Coloring Prompt on Health Engagement

In Need of a Pap Smear (Cervical Cancer Screening) | In Need of a Blood Pressure Check (Hypertension Screening) | In Need of a Cholesterol Test (Lipid Disorder Screening) | In Need of a Fasting Plasma Glucose Test (Diabetes)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States
Tufts Medical Center

Completed

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early (SAVE)

Plasma Cell Dyscrasia | Monoclonal Gammopathy

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Unusual Cancers of Childhood

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | Loss of Chromosome 17p

United States
University College, London

Unknown

Patient Controlled Fluid Administration

Hypovolemia | Dehydration (Physiology) | Thirst; Due to Deprivation of Water | Plasma Osmolality Increased

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Standardized Nursing Intervention Protocol for HCT Patients

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Psychosocial Effects of Cancer and Its Treatment | Myelodysplastic/Myeloproliferative Neoplasms | Therapy-related Toxicity

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Psychosocial Effects of Cancer and Its Treatment

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Psychosocial Effects of Cancer and Its Treatment

United States
Weill Medical College of Cornell University
Mayo Clinic; Janssen Scientific Affairs, LLC

Terminated

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory | Waldenstrom's Disease | Waldenström; Hypergammaglobulinemia | Waldenstrom's Macroglobulinemia of Lymph Nodes | Waldenstrom's Macroglobulinaemia, Without Mention of Remission

United States
Virginia Commonwealth University
Novartis Pharmaceuticals

Completed

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)

Prior Acute Myocardial Infarction | Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l) | Reduced Left Ventricle Ejection Fraction (<50%) | Symptoms of Heart Failure (NYHA Class II-III)

United States
Janssen Research & Development, LLC

Completed

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Multiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Neoplasm

United States, Belgium, Russian Federation
Yale University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

Hypertriglyceridemia | Steatohepatitis | Non Alcoholic Fatty Liver Disease | Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1

United States
Bristol-Myers Squibb

Completed

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

Multiple Myeloma

United States
All4Cure
Janssen Scientific Affairs, LLC

Recruiting

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

Multiple Myeloma | Multiple Myeloma Without Mention of Remission

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

Pain | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Psychosocial Effects of Cancer and Its Treatment | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals

Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Multiple Myeloma | Monoclonal Gammopathy of Renal Significance

United States
Massachusetts General Hospital
Kully Family Foundation

Unknown

Multiple Myeloma (MM) Quality of Life (QOL) Study

Quality of Life | Multiple Myeloma | Symptom, Behavioral

United States
Celularity Incorporated

Active, not recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemorrhagic Disorders | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Antineoplastic Agents | Physiological... and other conditions

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM

a Diagnosis of MGUS or SMM by IMWG Criteria

United States
The Cleveland Clinic

Completed

Screening for Systemic Amyloidosis Via the Ligamentum Flavum (ALF)

Amyloidosis | Spinal Stenosis | Amyloid | Transthyretin Amyloidosis | Primary Amyloidosis of Light Chain Type

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Multiple Myeloma | Plasmacytoma | Plasmacytoma of Bone

United States
Case Comprehensive Cancer Center

Withdrawn

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Myeloma | Smoldering Myeloma | Monoclonal Gammopathy

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
Dana-Farber Cancer Institute

Completed

Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

United States

Clinical Trials on Plasma Concentration of Mirabegron in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations